Distinct tumor protein p53 mutants in breast cancer subgroups

International Journal of Cancer

Volumn 132, Issue 5, 2013, Pages 1227-1231

  Dumay, Anne ^a   Feugeas, Jean Paul ^a   Wittmer, Evelyne ^a   Lehmann Che, Jacqueline ^a   Bertheau, Philippe ^a   Espié, Marc ^a   Plassa, Louis François ^a   Cottu, Paul ^b   Marty, Michel ^a   André, Fabrice ^c   Sotiriou, Christos ^d   Pusztai, Lajos ^e   De Thé, Hugues ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d JULES BORDET INSTITUTE   (Belgium)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

breast cancer; mutation patterns; p53; TP53

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; PROTEIN P63; PROTEIN P73;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE INACTIVATION; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; P63 GENE; P73 GENE; PRIORITY JOURNAL; TP53 GENE;

BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; MUTATION; NUCLEAR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84872835399     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27767     Document Type: Article

References (25)

1. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-23.
2. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24: 4660-71.
3. Guedj M, Marisa L, de Reynies A, et al. A refined molecular taxonomy of breast cancer. Oncogene 2011; 31: 1196-206.
4. Vousden KH, Lu X,. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
6. Oren M, Rotter V,. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107.
7. Bertheau P, Espie M, Turpin E, et al. TP53 status and response to chemotherapy in breast cancer. Pathobiology 2008; 75: 132-9.
8. Lehmann-Che J, Andre F, Desmedt C, et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 2010; 15: 246-52.
9. Pierga JY, Delaloge S, Espie M, et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 2010; 122: 429-37.
10. de Cremoux P, Valet F, Gentien D, et al. Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients. Biomed Chromatogr Cancer 2011; 11: 215.
11. Bertheau P, Turpin E, Rickman DS, et al. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 2007; 4: e90.
12. Coutant C, Rouzier R, Qi Y, et al. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 2011; 17: 2591-601.
13. Desmedt C, Di Leo A, de Azambuja E, et al. Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol 2011; 29: 1578-86.
14. Flaman JM, Frebourg T, Moreau V, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963-7.
15. Manie E, Vincent-Salomon A, Lehmann-Che J, et al. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 2009; 69: 663-71.
16. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-7.
17. Sorlie T,. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004; 40: 2667-75.
18. Maquat LE, Carmichael GG,. Quality control of mRNA function. Cell 2001; 104: 173-6.
19. Holstege H, Horlings HM, Velds A, et al. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. Biomed Chromatogr Cancer 2010; 10: 654.
20. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
21. Venitt S,. Mechanisms of spontaneous human cancers. Environ Health Perspect 1996; 104: 633-7.
22. Tseng JE, Rodriguez M, Ro J, et al. Gender differences in p53 mutational status in small cell lung cancer. Cancer Res 1999; 59: 5666-70.
23. Terry PD, Rohan TE,. Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev 2002; 11: 953-71.
24. Muller PA, Vousden KH, Norman JC,. p53 and its mutants in tumor cell migration and invasion. J Cell Biol 2011; 192: 209-18.
25. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40: 499-507.